22UA:ETR
BioNTech SE - ADR
€86.60
arrow_upward
+0.41%(+0.35) 1D
Sep 25, 5:35:45 PM GMT+2 · EUR
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 22UA...
Open
€87.30
High
€87.35
Low
€85.80
Mkt. cap
24.75B
Avg. vol.
52.52K
Volume
11.29K
52-wk high
€105.70
52-wk low
€68.30
No. of employees
8K
Open
€87.30
High
€87.35
Low
€85.80
Mkt. cap
24.75B
Avg. vol.
52.52K
Volume
11.29K
52-wk high
€105.70
52-wk low
€68.30
No. of employees
8K
News stories
From web sources and news partners
AD HOC NEWS
·
1 day ago
BioNTech stock last at EUR 87.05, down 0.46 percent in Xetra trading
Investing.com UK
·
1 day ago
Form 4 BioNTech SE For: 25 September By Investing.com
24/7 Wall St.
·
1 week ago
Moderna Climbs 6% as Cancer Vaccine Trade Extends a 137% Month; BioNTech and Novavax Edge Higher
Barron's
·
1 month ago
Pfizer Covid Pill Revenue Plunges 95%. The Stock Is Rising Anyway.
Profile
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology testing combination therapy approaches to improve treatment outcomes.
In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic. Wikipedia
About BioNTech SE - ADR